BioCardia (BCDA) Cash & Equivalents (2010 - 2026)

BioCardia (BCDA) has reported Cash & Equivalents for 16 consecutive years, with $4.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 320.1% year-over-year to $4.1 million in Q2 2026; TTM through Jun 2026 was $4.1 million, a 320.1% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 5.27% from the prior year.
• Cash & Equivalents was $4.1 million for Q2 2026 at BioCardia, up from $951000.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $8.6 million in Q2 2022 and troughed at $949000.0 in Q1 2024.
• A 5-year average of $3.7 million and a median of $3.3 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 85.02% in 2023 and jumped 320.1% in 2026, its largest moves.
• Over 5 years, Cash & Equivalents stood at $7.4 million in 2022, then tumbled by 85.02% to $1.1 million in 2023, then soared by 114.96% to $2.4 million in 2024, then rose by 5.27% to $2.5 million in 2025, then surged by 64.94% to $4.1 million in 2026.
• The last three Cash & Equivalents figures came in at $4.1 million (Q2 2026), $951000.0 (Q1 2026), and $2.5 million (Q4 2025), per Business Quant data.